Zhukova, T. O.Vasko, L. N.Nestulia, K. I.Aikian, A. Z.Mukovoz, O. E.Жукова, Тетяна ОлександрівнаВасько, Лариса МиколаївнаНестуля, Катерина ІгорівнаАйкян, Артем ЗавеновичМуковоз, Оксана ЄвгенівнаЖукова, Татьяна АлександровнаВасько, Лариса НиколаевнаНестуля, Катерина ИгоревнаАйкян, Артем ЗавеновичМуковоз, Оксана Евгеньевна2021-02-152021-02-152020-10Option therapeutic approach for primary breast cancer / T. O. Zhukova, L. N. Vasko, K. I. Nestulia, A. Z. Aikian, O. E. Mukovoz // Colloguium-journal. – 2020. – № 28 (80). – P. 24–27.2520-69902520-2480https://repository.pdmu.edu.ua/handle/123456789/14871Abstract. The first place in the ranking of oncology and the most acute oncology problem is breast cancer (BC), in the vast majority of women [1,2,3,5,18]. The rate of abstinence is high, and the percentage of patients receiving special therapy is 80.4%. All this indicates a low level of qualified care (Kolesnik O.O., Fedorenko Z.P., 2017). The aim of the study was the desire to study the effectiveness of various schemes of preoperative chemo-radiation therapy with radioimodification in the scheme of complex treatment of primary localized BC. Research results and their discussion. Analyzing 1 year of supervision, it is evident that 35 (83.3%) patients died in the I group, 7 died (16.7%). Patients who did not have a recurrence of the process at 1 year of life 25 (59.92%). In the II group, they died at 1 year - 6 (12.76%), and patients without relapsing 36 (76.59%). Comparing the result clearly that the overall survival of a reliable result was not low, and the rate of recurrence is likely to speak for the benefit of Group II. During second year , another 14 patients died in Group І against 7 group II. In the I survived, 21 (50,0%) were left, of which 17 (40,47%) without relapse were against 34 (72,34%) of the live ones, of which 20 (42,55%) without relapse. Summing up our research, supervision over the results of treatment in two groups, we can say that the remote survival results show the following: For 36 months. The observation formed the number of patients who clearly showed the results of treatment in groups I and II. In group І, overall survival rate was 11 (26,19%), with relapse 4 (9,52%). In the II group, the total number of patients with 3 years of observation was 25 (53,19%), with relapse of 17 (36,17%). Conclusions. The study of the effectiveness of the scheme of neoadjuvant chemo-therapy in combination with radiotherapy and radiomodification (group II) showed a positive trend in survival and relapse rates as well as a satisfactory state in the manifestations of toxicity of HT and radiation manifestations compared with the proposed scheme for group I.Изучение эффективности схемы неоад`ювантной химиотерапии в сочетании с лучевой терапией и радиомодификацией (II группа) выявило положительную тенденцию по показателям выживаемости и рецидивирования, а также удовлетворительное состояние в проявлениях токсичности ХТ и проявлений лучевых реакций в сравнении со схемой предложенной І группе. По результатам лечения в обеих группах, можно сказать, что отдаленные результаты выживаемости показывают следующее: на 36 мес. наблюдения: в первой группе общая выживаемость 11 (26,19%), из них с рецидивом 4 (9,52%). Во II группе общее количество больных на 3 год наблюдения 25 (53,19%), с рецидивом 17 (36,17%).enneoadjuvant chemotherapyprimary inoperable breast cancerbreastmultifractionradiomodificationнеоадъювантная химиотерапияпервично-неоперабельный рак грудной железыгрудная железамультифракционированиерадиомодификациянеоад'ювантна хіміотерапіяпервинно-неоперабельний рак грудної залозигрудна залозамультіфракціюваннярадіомодифікаціїArticle618.19-006-085